Related Experiment Video
Updated: Jul 2, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities
Shawyon Ezzati1, Samuel Salib1, Meenakshisundaram Balasubramaniam2
1California Northstate University College of Medicine, Elk Grove, CA 95757, USA.
Abstract:
Glioblastoma, a grade 4 glioma as per the World Health Organization, poses a challenge in adult primary brain tumor management despite advanced surgical techniques and multimodal therapies. This review delves into the potential of targeting epidermal growth factor receptor (EGFR) with small-molecule inhibitors and antibodies as a treatment strategy. EGFR, a mutationally active receptor tyrosine kinase in over 50% of glioblastoma cases, features variants like EGFRvIII, EGFRvII and missense mutations, necessitating a deep understanding of their structures and signaling pathways. Although EGFR inhibitors have demonstrated efficacy in other cancers, their application in glioblastoma is hindered by blood-brain barrier penetration and intrinsic resistance. The evolving realm of nanodrugs and convection-enhanced delivery offers promise in ensuring precise drug delivery to the brain. Critical to success is the identification of glioblastoma patient populations that benefit from EGFR inhibitors. Tools like radiolabeled anti-EGFR antibody 806i facilitate the visualization of EGFR conformations, aiding in tailored treatment selection. Recognizing the synergistic potential of combination therapies with downstream targets like mTOR, PI3k, and HDACs is pivotal for enhancing EGFR inhibitor efficacy. In conclusion, the era of precision oncology holds promise for targeting EGFR in glioblastoma, contingent on tailored treatments, effective blood-brain barrier navigation, and the exploration of synergistic therapies.
Insights
Targeting epidermal growth factor receptor (EGFR) offers promise for glioblastoma treatment. Overcoming challenges like blood-brain barrier penetration and resistance through precision medicine and combination therapies is key for improved patient outcomes.
Area of Science:
- Neuro-oncology
- Molecular biology
- Drug development
Background:
- Glioblastoma (WHO grade 4 glioma) presents significant challenges in adult primary brain tumor management.
- Epidermal growth factor receptor (EGFR) is a critical therapeutic target, found mutated in over 50% of glioblastoma cases, including variants like EGFRvIII and EGFRvII.
Purpose of the Study:
- To review the potential of targeting epidermal growth factor receptor (EGFR) using small-molecule inhibitors and antibodies for glioblastoma treatment.
- To explore strategies for overcoming therapeutic resistance and blood-brain barrier limitations in glioblastoma.
Main Methods:
- Review of current literature on EGFR mutations, signaling pathways, and therapeutic strategies in glioblastoma.
- Discussion of emerging drug delivery systems, including nanodrugs and convection-enhanced delivery.
- Exploration of diagnostic tools for patient stratification and combination therapy approaches.
Main Results:
- EGFR inhibitors show promise but face hurdles in glioblastoma, including blood-brain barrier penetration and intrinsic resistance.
- Nanodrugs and convection-enhanced delivery offer potential solutions for targeted brain drug delivery.
- Radiolabeled anti-EGFR antibody 806i aids in visualizing EGFR conformations for tailored treatment selection.
Conclusions:
- Precision oncology, focusing on tailored EGFR-targeted treatments, is a promising avenue for glioblastoma.
- Effective blood-brain barrier navigation and combination therapies targeting downstream pathways (mTOR, PI3k, HDACs) are crucial for enhancing efficacy.
